Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015

Antiviral Research

Volumn 132, Issue , 2016, Pages 178-185

  Hurt, Aeron C ^a,b   Besselaar, Terry G ^c   Daniels, Rod S ^d   Ermetal, Burcu ^d   Fry, Alicia ^e   Gubareva, Larisa ^e   Huang, Weijuan ^f   Lackenby, Angie ^g   Lee, Raphael T C ^h   Lo, Janice ⁱ   Maurer Stroh, Sebastian ^h,j,k   Nguyen, Ha T ^e   Pereyaslov, Dmitriy ^c   Rebelo de Andrade, Helena ^l,m   Siqueira, Marilda M ⁿ   Takashita, Emi ^o   Tashiro, Masato ^o   Tilmanis, Danielle ^a   Wang, Dayan ^f   Zhang, Wenqing ^c   Meijer, Adam ^p   more..

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f National Institute for Viral Disease Control and Prevention   (China)

^g PUBLIC HEALTH ENGLAND   (United Kingdom)

^h BIOINFORMATICS INSTITUTE   (Singapore)

ⁱ Public Health Laboratory Centre   (Hong Kong)

^j NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^k MINISTRY OF HEALTH   (Singapore)

^l NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^m RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

ⁿ INSTITUTO OSWALDO CRUZ   (Brazil)

^o NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^p NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

more..

Author keywords

Antiviral resistance; Global analysis; Influenza virus; Neuraminidase inhibitors; Oseltamivir; Reduced susceptibility

Indexed keywords

AMINO ACID; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR; ANTIVIRUS AGENT; NA PROTEIN, INFLUENZA A VIRUS; SIALIDASE; VIRAL PROTEIN;

2009 H1N1 INFLUENZA; AMINO ACID SUBSTITUTION; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; B VICTORIA LINEAGE VIRUS; B YAMAGATA LINEAGE VIRUS; HUMAN; IC50; INFLUENZA; INFLUENZA A (H3N2); INFLUENZA VIRUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE DATABASE; VIRUS INHIBITION; WORLD HEALTH ORGANIZATION; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; CLASSIFICATION; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; FACTUAL DATABASE; GENETICS; GLOBAL HEALTH; HEALTH SURVEY; HISTORY; INFLUENZA A VIRUS; MICROBIAL SENSITIVITY TEST; MUTATION; VIROLOGY;

ANTIVIRAL AGENTS; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; GLOBAL HEALTH; HISTORY, 21ST CENTURY; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MICROBIAL SENSITIVITY TESTS; MUTATION; NEURAMINIDASE; POPULATION SURVEILLANCE; VIRAL PROTEINS; WORLD HEALTH ORGANIZATION;

EID: 84976384129     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.06.001     Document Type: Article

References (17)

1. Abed, Y., Pizzorno, A., Bouhy, X., Boivin, G., Permissive changes in the neuraminidase play a dominant role in improving the viral fitness of oseltamivir-resistant seasonal influenza A(H1N1) strains. Antivir. Res. 114 (2015), 57–61.
2. Butler, J., Hooper, K.A., Petrie, S., Lee, R., Maurer-Stroh, S., Reh, L., Guarnaccia, T., Baas, C., Xue, L., Vitesnik, S., Leang, S.K., McVernon, J., Kelso, A., Barr, I.G., McCaw, J.M., Bloom, J.D., Hurt, A.C., Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses. PLoS Pathog., 10, 2014, e1004065.
3. Deng, Y.M., Spirason, N., Iannello, P., Jelley, L., Lau, H., Barr, I.G., A simplified Sanger sequencing method for full genome sequencing of multiple subtypes of human influenza A viruses. J. Clin. Virol. 68 (2015), 43–48.
4. Dharan, N.J., Gubareva, L.V., Meyer, J.J., Okomo-Adhiambo, M., McClinton, R.C., Marshall, S.A., St, G.K., Epperson, S., Brammer, L., Klimov, A.I., Bresee, J.S., Fry, A.M., Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301 (2009), 1034–1041.
5. Hurt, A.C., Ernest, J., Deng, Y., Iannello, P., Besselaar, T.G., Birch, C., Buchy, P., Chittaganpitch, M., Chiu, S.C., Dwyer, D.E., Guigon, A., Harrower, B., Kei, I.P., Kok, T., Lin, C., McPhie, K., Mohd, A., Olveda, R., Panayotou, T., Rawlinson, W., Scott, L., Smith, D., D'Souza, H., Komadina, N., Shaw, R., Kelso, A., Barr, I.G., Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antivir. Res. 83 (2009), 90–93.
6. Hurt, A.C., Hardie, K., Wilson, N.J., Deng, Y.M., Osbourn, M., Gehrig, N., Kelso, A., Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N. Engl. J. Med. 365 (2011), 2541–2542.
7. Kawai, N., Ikematsu, H., Hirotsu, N., Maeda, T., Kawashima, T., Tanaka, O., Yamauchi, S., Kawamura, K., Matsuura, S., Nishimura, M., Iwaki, N., Kashiwagi, S., Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007–2008 and 2008–2009 influenza seasons. Clin. Infect. Dis. 49 (2009), 1828–1835.
8. Kawai, N., Ikematsu, H., Iwaki, N., Kondou, K., Hirotsu, N., Kawashima, T., Maeda, T., Tanaka, O., Doniwa, K., Kashiwagi, S., Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. J. Infect. 59 (2009), 207–212.
9. Lackenby, A., Hungnes, O., Dudman, S., Meijer, A., Pajet, W., Hay, A.J., Zambon, M.C., Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill., 13, 2008, 5.
10. Little, K., Leang, S.K., Butler, J., Baas, C., Harrower, B., Mosse, J., Barr, I.G., Hurt, A.C., Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring. Euro Surveill., 20, 2015, 30060.
11. Meijer, A., Lackenby, A., Hungnes, O., Lina, B., van der Werf, S., Schweiger, B., Opp, M., Paget, J., van de Kassteele, J., Hay, A., Zambon, M., Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007–08 season. Emerg. Infect. Dis. 15 (2009), 552–560.
12. Meijer, A., Rebelo-de-Andrade, H., Correia, V., Besselaar, T., Drager-Dayal, R., Fry, A., Gregory, V., Gubareva, L., Kageyama, T., Lackenby, A., Lo, J., Odagiri, T., Pereyaslov, D., Siqueira, M.M., Takashita, E., Tashiro, M., Wang, D., Wong, S., Zhang, W., Daniels, R.S., Hurt, A.C., Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013. Antivir. Res. 110 (2014), 31–41.
13. Okomo-Adhiambo, M., Nguyen, H.T., Sleeman, K., Sheu, T.G., Deyde, V.M., Garten, R.J., Xu, X., Shaw, M.W., Klimov, A.I., Gubareva, L.V., Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antivir. Res. 85 (2010), 381–388.
14. Potier, M., Mameli, L., Belisle, M., Dallaire, L., Melancon, S.B., Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal. Biochem. 94 (1979), 287–296.
15. Takashita, E., Kiso, M., Fujisaki, S., Yokoyama, M., Nakamura, K., Shirakura, M., Sato, H., Odagiri, T., Kawaoka, Y., Tashiro, M., Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013–2014 influenza season in Japan. Antimicrob. Agents Chemother. 59 (2015), 2607–2617.
16. Takashita, E., Meijer, A., Lackenby, A., Gubareva, L., Rebelo-de-Andrade, H., Besselaar, T., Fry, A., Gregory, V., Leang, S.K., Huang, W., Lo, J., Pereyaslov, D., Siqueira, M.M., Wang, D., Mak, G.C., Zhang, W., Daniels, R.S., Hurt, A.C., Tashiro, M., Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014. Antivir. Res. 117 (2015), 27–38.
17. WHO, Meetings of the WHO working group on surveillance of influenza antiviral susceptibility - Geneva, November 2011 and June 2012. Wkly. Epidemiol. Rec. 87 (2012), 369–374.